Dr. Edgardo Santos' Interview with Mitesh Borad, MD
Update: 2025-08-25
Description
Interviews with Summit Director Edgardo S. Santos Castillero, MD, FACP, FASCO
NOSCM 2024 | New Orleans SummerCancer Meeting
Dr. Edgardo Santos' Interview with Mitesh Borad, MD
Dr. Borad highlighted that RMC-6236’s targeting of KRASin refractory pancreatic cancer achieved 90% disease control and an 8-month median PFS, while cholangiocarcinoma now benefits from IDH and FGFR inhibitors and promising HER2-targeted antibodies (zanidatamab, trastuzumab). In HCC, dualcheckpoint blockade with ipilimumab plus nivolumab has delivered over 30% response rates and 30–40% two- to three-year survival, underscoring the impact of precision and immunotherapy across these malignancies.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
